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ABSTRACT: In an effort to determine its cytotoxicity as well as antigen specific immune activity of aqueous 
leaves extract of Strychnos nux-vomica using hepatitis B vaccine containing surface antigen (HBsAg; 20 
µg/ml) pertaining to antibody production and scrutinize its proliferative response along with cytokines in 
lysed human whole blood. For these studies, phytochemical (qualitative) analysis was determined and 
evaluates the presence of secondary metabolites through high performance thin layer chromatography 
(HPTLC) and bio-inorganic fingerprinting. In addition, indirect Elisa was performed using HBsAg as coating 
antigen using variable doses (1-30 mg/ml) of Strychnos nux-vomica. In continuation of these immunological 
studies, antigen specific immune response along with cytotoxicity was determined through MTT assay in 
infected human whole blood using HBsAg (20 µg/ml, 50 µl). The results showed that Strychnos nux-vomica 
showed qualitatively as well as quantitatively determined the presence of secondary metabolites along with 
bio-inorganic compounds. In addition, Strychnos nux-vomica showed enhancement in anti-HBsAg IgG titre as 
compared to standard and control but there is sudden decline in proliferation with HBsAg and also showed 
decline in cytokines (IL-2 and IL-12) level at higher doses as compared to control. Our data suggest that 
Strychnos nux-vomica may help to raise antibodies against HBsAg but sudden decline in HBsAg proliferative 
response along with cytokines (IL-2 and IL-12) in infected lysed human whole blood and also showed some 
cytotoxic effect at higher doses. In other words, Strychnos nux-vomica could be a potent immune enhancer of 
B cells and inhibitor of T cells against HBsAg. 
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1. INTRODUCTION 
 Medicinal plant products showed numerous properties related to human health care. In other words, 
these medicinal plant products played a significant effect were reported in case of human especially reported 
in the prevention of various pathogenic diseases [1, 2]. As per the literature, various medicinal plant products 
were considered as immunomodulator e.g. immunostimulator (help combat viral infection such as aids and 
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cancer), immunosuppressor (preventing rejection of transplanted organs) and immunoadjuvants (enhancing 
humoral or cell mediated immune response) [1-5]. So, these immunomodulators provide some alternative in 
comparison with conventional chemotherapy for a variety of intracellular (viral) diseases along with 
autoimmune disorders where selective type of immunosuppressant is used [4-6]. In view of this, most of the 
medicinal plant products may be in the form of primary and secondary metabolites which constitute a 
common alternative treatment of immunocompromised patients in many countries around the world.  
 Out of these, one of the medicinal plant i.e. Strychnos nux-vomica (commonly known as Kuchla) 
belonging to the family Loganiaceae, which is commonly found in and grows in Sri Lanka, India 
(Maharashtra) and Australia. Strychnos nux-vomica L. (SN) is widely used in Indian traditional medicine 
(Ayurveda) for treating a wide range of ailments which include paralysis, diabetes, gonorrhea, anemia, 
bronchitis, etc. [7-12]. It is also known to possess antioxidant and anti-snake venom activity [13]. The 
chemical composition of SN is mainly comprised of indole alkaloids. The major alkaloids are strychnine and 
brucine, which are being employed clinically as efficient stimulants of nervous system [13-25]. In traditional 
Chinese medicine, Strychnos nux-vomica (Fig. 1) has been employed for the treatment of liver cancer. The 
crude extracts and purified alkaloids from Strychnos nux-vomica have been shown to inhibit the growth of 
various cancer cell lines in vitro. In spite of numerous therapeutic effects of Strychnos nux-vomica, its effect 
on hematologic malignancies is still ill-defined. Due to the lack of awareness about its medicinal properties of 
Strychnos nux-vomica, it is used very less for therapeutic purposes.  
 
 
Figure 1. Strychnos nux-vomica. 
 
 Recently, more than 84 compounds were reported in the form of secondary metabolites i.e. alkaloids, 
iridoid glycosides, flavonoid glycosides, triterpenoids, steroids and organic acids, among others, have been 
isolated, purified and identified its structure from Strychnos nux-vomica [13-25]. In other words, these 
compounds in the form of secondary metabolites possess an array of immunobiological activities, including 
its effects on the nervous system, analgesic and anti-inflammatory actions, anticancer effect, declining in the 
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growth of various pathogenic microorganisms etc. According to the literature of this plant, Strychnos nux-
vomica which is already reported as anti-bacterial, anti-hyperglycemic and anti-oxidative activities. Apart 
from these medicinal properties, uses of this medicinal plant products are also reported e.g. Seeds used in 
atonic dyspepsia, tincture used in mixtures or its stimulant action on gastro intestinal tract. It stimulates 
peristalsis; strychnine is used as a gastric tonic in dyspepsia. Brucine is used in pruritus and as a local anodyne 
in inflammations of the external ear; root is biter, aphrodisiac, tonic. It is effective for skin diseases of scaly 
nature, leprosy, eczema and scabies [13-25]. It is blood purifier and is therefore helpful in curing skin 
disorders and allergies. It regulates the histamine secretion and helps building immunity to fight against 
various allergens. It is also good for inflammation, chronic pains in the muscles and joints; leaves are 
normally applied as a poultice especially on sloughing wounds and also applied on ulcers as well. These are 
also applied as well as in the preparation or synthesis of medicated product for hair as well as scalp [13-25]. 
In view of this literature, leaves of this medicinal plant were investigated its effect on antigen specific immune 
response. 
2. MATERIALS AND METHODS 
2.1. Reagents and antibodies 
 HBsAg vaccine (Serum Institute of India), horse antiserum, 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT; Himedia), capture and detection antibody IL-2 and IL-12 (BD optia Elisa kit). 
2.2. Botanical description and demand of plant product 
 There is a growing demand in pharmaceutical companies especially for fruits/seeds of this species i.e. 
Strychnos nux-vomica. One of the most familiar example is seen where the demand for Strychnos nux-vomica 
fruits in Maharashtra state of India alone as 300 kg per year. Numerous effects were taken by various 
researchers in order to enhance the production of raw material and used by various pharmaceutical companies. 
So, there is urgent need in order to enhance its production rate and paid more attention to cultivation of 
medicinal plants. In this case, seed propagation is one of the most often used and cheapest method, knowledge 
of seed handling is a prerequisite for growing this species successfully. Till now, there is no information 
related to the seeds of Strychnos nux-vomica possess dormancy. For ex situ conservation purposes related to 
this plant i.e. seed storage behavior i.e., desiccation sensitivity, temperature of storage along with moisture 
content of the seeds including longevity of the seeds in storage, should be known. 
2.3. HPTLC analysis and bio-inorganic fingerprinting of leaves 
 The plant was washed with sufficient quantity of distilled water. For the preparation of aqueous 
extract, leaf sample was macerated to finely powder form and this was used for the immunological studies. 
The aqueous extraction usually done in phosphate buffered saline and crushed in a mortar pestle and the 
extract was centrifuged at 10000 rpm at 4°C for 10 minutes. The supernatant was collected and revealed the 
presence of terpenoids, flavonoids and phenolics. For confirmation, this sample was used for HPTLC analysis 
and bio-inorganic fingerprinting (using atomic absorption spectrometer analysis) of leaves of Strychnos nux-
vomica. The solvents including purified reagents along with HPTLC plates (10 x 10 cm) were purchased from 
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Qualigens and Merck. The stock solution of the leaves of Strychnos nux-vomica was prepared for HPTLC 
studies and dissolved the leaves in phosphate buffered saline or with different solvents. Plate was scanned by 
using densitometric scanner.  
 For bio-inorganic fingerprinting, air was generally allowed pertaining to mix with acetylene gas (using 
gas cylinder, good proportion to ignite the burner of the spectrophotometer). After ignition, calibrate the 
spectrophotometer using blank (distilled water) and also standard solution (as supplied with the 
spectrophotometer) as well. Finally, sample aerosol was then aspirated through nebulizer into the flame for 
analysis. Analysis was done for detecting these elements at their specific wavelength using hollow cathode 
lamp and its result is displayed on the computer read-out. 
2.4. ELISA 
 Indirect Elisa was performed using standard HBsAg vaccine (1:1000 dilution) as coating antigen. 
Variable concentrations of Strychnos nux-vomica were added and determined its anti-HBsAg titre. Anti-
HBsAg serum was used as standard for the estimation of IgG antibody titre. Horse anti-serum used as 
secondary antibody and absorbance in the form of optical density measured at 450 nm [26]. 
2.5. Immunopharmacological activity 
 Determination its immunopharmacological activity on the basis of its bioassays for measuring its 
cytotoxic (MTT assay in human whole blood) and antigen specific immune activity (lymphocyte proliferation 
assay using HBsAg and estimating cytokines i.e. IL-2 and IL-12 as well through Elisa activity) of Strychnos 
nux-vomica. 
2.5.1. Cytotoxicity and anti-inflammatory activity 
 Lysed human whole blood (106 cells/ml; 100 µl) were taken in 96 well plate in absence or presence of 
HBsAg (20 µg/ml; 10 µl) vaccine for 24 h incubation in carbon dioxide incubator along with variable 
concentration of Strychnos nux-vomica in a final volume of 0.2 ml. Centrifuging the plate, collect the 
supernatant for the estimation of cytokines. After collection, add MTT (5 mg/ml; 10 µl) solution in 96 well 
plates. Incubate the plate for another 2-3 h and observed formazan crystals settled at the bottom. These 
crystals were dissolved in dimethyl sulphoxide and the optical density was measured at 570 nm [27, 28] using 
microplate reader (Bio-Rad Laboratories India). 
2.5.2. Estimation of cytokines 
 Th1 (IL-2 and IL-12) were measured with an enzyme linked immunosorbent assay (BD optia kit) 
according to the instructions of the manufacturer [29]. In this kit, add ELISA diluent (50 μl) into each well (96 
well Elisa plate; high protein binding) and also add standard or sample (100 μl). So, incubate these samples 
for 2 h at room temperature. Thereafter, aspirate and wash the sample including standard five times. Add 
working detector (100 μl) to each well and then incubate these samples for one hour at room temperature. 
Finally, aspirate and wash these samples (seven times) and then add TMB (100 μl) substrate reagent to each 
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well. Incubate these samples at room temperature and then add stop solution (50 μl) to each well. Read these 
samples at 450 nm within 30 minutes. 
2.6. Statistical analysis  
 The difference between control, standard and Strychnos nux-vomica is determined by Bonferroni 
multiple comparison test (One way ANOVA test). 
3. RESULTS 
3.1. ELISA 
 The results of these studies may indicate that Strychnos nux-vomica showed higher antibody 
production at higher doses as compared to control (Fig. 2). 
 
 
Figure 2. ELISA assay. Indirect Elisa was performed using standard HBsAg as coating antigen. Variable concentration of 
Strychnos nux-vomica was used for the estimation of anti-HBsAg antibody titre. Horse anti-serum used as secondary 
antibody and optical density measured at 450 nm. The difference between the control and standard is determined by one 
way ANOVA test. *P<0.05; **P < 0.01 and ***P < 0.001. 
 
3.2. HPTLC analysis and Bio-inorganic fingerprinting 
 The mobile phase for Strychnos nux-vomica was ethyl acetate: n-butanol in the ratio of 3:2. So, 
resolution for Strychnos nux-vomica was obtained at 220 nm. The results showed that maximum 
concentration with an area under the curve of 200 and its peaks also obtained at 1.21. In terpenoids, Strychnos 
nux-vomica showed its presence in retention factor (RF) value i.e. 0.93. In addition, bio-inorganic 
fingerprinting of Strychnos nux-vomica is done by using atomic absorption spectroscopy (AAS). Strychnos 
nux-vomica plant leaves are analyzed for trace metal contents- copper (Cu), iron (Fe), magnesium (Mg), 
manganese (Mn), calcium (Ca) and zinc (Zn). Sample preparation was done in both water and HCl. Data is 
recorded in ppm. The aqueous extract showed the presence of Cu (0.26), Fe (0.34), Mn (4.42), Mg (0.11), Ca 
(4.99) and Zn (0.644). Further studies are taken, HPLC analysis of the aqueous extract it was observed that it's 
totally endotoxin free fraction.  
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3.3. MTT assay 
 In cytotoxicity based assay, MTT assay is generally used for determining dose response curve of 
Strychnos nux-vomica against HBsAg (Fig. 3). From these studies, it showed inhibitory effect at higher doses 
in human whole blood after exposure with variable concentration of Strychnos nux-vomica. This activity is 




Figure 3. Inhibition of antigen specific immune response using HBsAg in human whole blood which is determined 
through MTT assay. Values are expressed as Mean ± S.E. Statistical analysis is performed between control vs standard; 
standard vs variable concentration. *P<0.05; **P<0.01 and ***P<0.001 
 
 
Figure 4. Estimation of cytokines from cell culture supernatant in lysed human whole blood containing HBsAg. Values 
are expressed as Mean ± S.E. Statistical analysis is performed between control vs standard; standard vs variable 
concentration. *P<0.05; **P<0.01 and ***P<0.001 
 
3.4. Estimation of cytokines 
 In anti-inflammatory studies, following assays were used i.e. lymphocyte proliferation assay using 
HBsAg and also measuring cytokines from cell culture supernatant. The result of these studies related to 
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Strychnos nux-vomica which inhibits T cell immunity with respect to HBsAg (specific antigen) can be shown 
by the reduction of lymphocyte proliferation response. In other words, Strychnos nux-vomica may 
significantly decreases the activation potential of T cells observed in human whole blood. For confirmation, 
Elisa test were performed for determining cytokines from human whole blood cell culture supernatant in 
presence of Strychnos nux-vomica extracted treated with HBsAg. The results may clear cut indication that 
Strychnos nux-vomica showed significant effect on IL-2 and IL-12 cytokines, thereby confirming its 
inhibitory effect on the cell-mediated immune response (Fig. 4).  
4. DISCUSSION 
 Medicinal plants are widely useful and also claimed to be very effective in the treatment of various 
diseases especially using various traditional systems of medicine. Various Strychnos species are already 
reported traditionally e.g. S. potatorum, used in the treatment of cardiovascular disease i.e. diabetes and is 
found to be every effective. Considering these facts, this study deals with the evaluation of cytoxicity and 
anti-inflammatory activity in Strychnos nux-vomica [13-18]. Till date, numerous chemical compounds 
especially strychnine and brucine are already reported and isolated from different plant parts of Strychnos 
nux-vomica and considered them as major active principle which is responsible for its therapeutic potential 
and toxicity [13-25].  
 Availability of current treatment are there in order to control various types of immunopathological 
disorders only using various types of immunosuppressive drugs. In this regard, various approaches should be 
taken pertaining to induce or suppress antigen specific immunological tolerance that has the ability to induce 
or control or suppress cellular as well as humoral immune responses at the appropriate level. These type of 
responses are generally desirable in order to maintain and regulating the proper immune system. However, 
further immunopharmacological research should be designed pertaining to determine its cytotoxicity and 
antigen specific immune activity of Strychnos nux-vomica in human whole blood. The results showed that 
Strychnos nux-vomica showed decline its activity in presence or absence of HBsAg antigen in lysed human 
whole blood, thereby supporting its cytotoxic as well as declining in antigen specific immune properties. Both 
these activities could be possible only due to the presence of secondary metabolites that are reported in 
Strychnos nux-vomica. 
 The effect of Strychnos nux-vomica at various concentrations on lysed human whole blood and was 
evaluated its cytotoxicity against HBsAg using MTT assay. The optical density of proliferation of 
lymphocytes at different concentrations and showing that Strychnos nux-vomica inhibited HBsAg 
stimulations at higher concentrations. In other words, Strychnos nux-vomica indicates its potential as an 
effective immunosuppressive compound. In addition, inhibition of HBsAg specific immune response is 
mainly due to decline in T lymphocytes production in case of human lysed whole blood. According to the 
literature, T lymphocytes may play a central role seen in case of antigen (e.g. HBsAg) specific immune 
response against various pathogens [29]. Finally, our data show that Strychnos nux-vomica decline in the 
proliferation of T cells in human lysed whole blood with respect to HBsAg stimulation. Overall, the data 
reveals that Strychnos nux-vomica decrease HBsAg proliferation rate at higher doses.  
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 Modulation of cytokine secretion in the form of stimulation or suppression showed some novel 
approaches for the treatment of various diseases [29]. One of the observation is seen in case of Strychnos nux-
vomica showed some modulation i.e. inhibition in cytokine expression. IL-12 is a cytokine released by DCs 
which can induce differentiation of T cells to Th1 and cellular immunity. Our results showed that Strychnos 
nux-vomica decreased production of IL-12 comparing with control however this change was highly 
significant. In addition, Strychnos nux-vomica decreased production of IL-2 cytokine but this change was also 
significant. This inhibitory activity of Strychnos nux-vomica is controlled by various mediators i.e. cytokines 
such as IL-2 and IL-12 cytokines. These cytokines are probably the most valuable mediator of anti-microbial 
and anti-tumoral defense and these cytokines have the ability to destroy vital cellular structures like lipids and 
proteins and to inhibit growth and proliferation of cells and pathogens [29]. These studies may be confirmed 
that Strychnos nux-vomica significantly decreased IL-2 and IL-12 cytokine production. 
5. CONCLUSION 
 Aqueous leaves extracts of Strychnos nux-vomica showed some cytotoxic as well as inhibition in 
antigen specific immune activity in lysed human whole blood using HBsAg. This medicinal plant might be of 
some value especially in case of T cell mediated disorders i.e. autoimmune disease. Further type of 
immunopharmacological should be done pertaining to determine the exact phytoconstituents or secondary 
metabolites that are responsible for inhibiting T cell proliferation. 
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